GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Operating Cash Flow per Share

PEPG (PepGen) Operating Cash Flow per Share : $-2.54 (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is PepGen Operating Cash Flow per Share?

PepGen's operating cash flow per share for the three months ended in Mar. 2025 was $-0.70. PepGen's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.54.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for PepGen's Operating Cash Flow per Share or its related term are showing as below:

PEPG' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -138.4   Med: -67.3   Max: 3.8
Current: 3.8

During the past 5 years, PepGen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.80% per year. The lowest was -138.40% per year. And the median was -67.30% per year.

PEPG's 3-Year OCF Growth Rate is ranked worse than
55.88% of 1217 companies
in the Biotechnology industry
Industry Median: 9.3 vs PEPG: 3.80

PepGen Operating Cash Flow per Share Historical Data

The historical data trend for PepGen's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen Operating Cash Flow per Share Chart

PepGen Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Operating Cash Flow per Share
-0.21 -2.93 -3.79 -2.90 -2.61

PepGen Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.50 -0.74 -0.60 -0.70

Competitive Comparison of PepGen's Operating Cash Flow per Share

For the Biotechnology subindustry, PepGen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PepGen's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PepGen's Price-to-Operating-Cash-Flow falls into.


;
;

PepGen Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

PepGen's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )=Cash Flow from Operations (A: Dec. 2024 )/Shares Outstanding (Diluted Average) (A: Dec. 2024 )
=-82.372/31.583
=-2.61

PepGen's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )=Cash Flow from Operations (Q: Mar. 2025 )/Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
=-22.93/32.675
=-0.70

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PepGen Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of PepGen's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PepGen Business Description

Industry
Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
James G Mcarthur director, officer: President and CEO NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Noel Donnelly officer: Chief Financial Officer PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Michelle L Mellion officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jaya Goyal officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton director PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C) 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Sonia Bracegirdle officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p. 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p. 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017